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Although, better known for its role in inflammation, the transcription factor nuclear factor
kappa B (NF-κB) has more recently been implicated in synaptic plasticity, learning,
and memory. This has been, in part, to the discovery of its localization not just in
glia, cells that are integral to mediating the inflammatory process in the brain, but
also neurons. Several effectors of neuronal NF-κB have been identified, including
calcium, inflammatory cytokines (i.e., tumor necrosis factor alpha), and the induction of
experimental paradigms thought to reflect learning and memory at the cellular level (i.e.,
long-term potentiation). NF-κB is also activated after learning and memory formation
in vivo. In turn, activation of NF-κB can elicit either suppression or activation of other
genes. Studies are only beginning to elucidate the multitude of neuronal gene targets of
NF-κB in the normal brain, but research to date has confirmed targets involved in a wide
array of cellular processes, including cell signaling and growth, neurotransmission, redox
signaling, and gene regulation. Further, several lines of research confirm dysregulation
of NF-κB in Alzheimer’s disease (AD), a disorder characterized clinically by a profound
deficit in the ability to form new memories. AD-related neuropathology includes the
characteristic amyloid beta plaque formation and neurofibrillary tangles. Although, such
neuropathological findings have been hypothesized to contribute to memory deficits in
AD, research has identified perturbations at the cellular and synaptic level that occur
even prior to more gross pathologies, including transcriptional dysregulation. Indeed,
synaptic disturbances appear to be a significant correlate of cognitive deficits in AD.
Given the more recently identified role for NF-κB in memory and synaptic transmission in
the normal brain, the expansive network of gene targets of NF-κB, and its dysregulation
in AD, a thorough understanding of NF-κB-related signaling in AD is warranted and may
have important implications for uncovering treatments for the disease. This review aims
to provide a comprehensive view of our current understanding of the gene targets of
this transcription factor in neurons in the intact brain and provide an overview of studies
investigating NF-κB signaling, including its downstream targets, in the AD brain as a
means of uncovering the basic physiological mechanisms by which memory becomes
fragile in the disease.
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First described in the context of immunity, NF-κB is gaining
acceptance as a key transcriptional regulator of learning and
memory. The present review will address NF-κB in the general
context of learning and memory as it relates to the literature
in AD, the devastating age-related dementia characterized by
extracellular amyloid beta (Aβ) plaques, hyperphosphorylated-
tau-containing neurofibrillary tangles (NFTs), severe loss of
neurons, and cognitive deficits, particularly those related to
memory. As we (Snow et al., 2014) and others (Salles et al., 2014;
Engelmann and Haenold, 2016) have recently reviewed the role
of NF-κB in synaptic plasticity and cognition elsewhere, this topic
will not be addressed at length here.
NF-κB AND ITS ACTIVATION
The activation of NF-κB is multifaceted; in an inactive state, this
molecule consists of either homo- or heterodimers of various
subunit compositions (i.e., p50, p52, p65, which is also called
RelA, RelB, and c-Rel) in the cytoplasm, with dimers bound by
the inhibitory protein IκB (Zheng et al., 2011). In neurons, the
most common composition consists of the p65, p50, and IκBα
subunits (Mincheva-Tasheva and Soler, 2013). In the canonical
activation pathway, NF-κB becomes activated by a series of
neurochemical events that are initiated upon activation of IκB
kinase (IKK). IKK activation results in degradation of IκB via
phosphorylation (IκBα at Ser32 and Ser36; IκBβ at Ser19 and Ser23;
Hayden and Ghosh, 2004), and, upon release of IκB, the resulting
dimer becomes activated, translocates to the nucleus, and binds
to the DNA consensus sequence of its gene targets, where it
can either induce or suppresses gene expression (Zhong et al.,
2002). One such target of NF-κB transcription is IκB, thereby
providing a negative feedback mechanism to tightly regulate NF-
κB-dependent gene transcription (Sun et al., 1993; see Figure 1).
Although, activation of NF-κB is classically initiated by
IKK activation and IκB degradation, other activation pathways
have been identified. For example, NF-κB activation can also
occur via an IKK-independent mechanism. Here, tyrosine
phosphorylation of IκB results in release of the dimer without IκB
degradation (Imbert et al., 1996). Still a third activation pathway
has been identified, with IKK becoming activated by NF-κB-
inducing kinase, which causes processing of the p100 subunit
to the p52 form prior to dimer translocation to the nuclear
(Sun, 2011). Upon dimer release, posttranslational modifications
can also alter NF-κB activity. For example, protein kinase A
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BACE1, Beta-site APP cleaving enzyme 1; BDNF, Brain-derived neurotrophic
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Postsynaptic density protein-95; PS1, Presenilin 1; PKA, Protein kinase A;
PKC, Protein kinase C; ROS, Reactive oxygen species; sAPPβ, Secreted amyloid
precursor protein beta; TNF, Tumor necrosis factor.
(PKA) can induce phosphorylation of the p65 subunit in its
active form (i.e., after sequestration from IκB), resulting in
enhanced p65 binding at the nucleus (Zhong et al., 1998).
However, this pathway can also inhibit gene expression, as PKA-
phosphorylated p65 can associate with nuclear RelB, creating a
heterodimer that is unable to bind to DNA, thereby reducing
NF-κB activation at the nucleus (Jacque et al., 2005). Further
specificity of activity can be achieved by the precise location of
posttranslational modifications to p65. For example, acetylation
of p65 at Lys-122 and 123 results in diminished transcription
(Kiernan et al., 2003), whereas acetylation of p65 at Lys-
310 results in enhancements (Chen L. F. et al., 2002, 2005).
Thus, the activation of cytoplasmic NF-κB is complex and
under the regulation of multiple mechanisms via numerous
pathways.
ACTIVATORS OF NF-κB IN NEURONS
Several activators of NF-κB from a broad range of functional
categories have been identified in neurons. Of particular
relevance to AD is the finding that amyloid beta (Aβ) peptides
can induce NF-κB activation in both neurons (see Figure 1) and
astrocytes (discussed in detail below).
The cytokine tumor necrosis factor α (TNFα), implicated
in the inflammatory response after tissue injury, is among the
most well-studied and well-known activators of NF-κB in both
neuronal and non-neuronal cells. TNFα is exquisitely linked with
NF-κB, as it serves as both an activator (Collart et al., 1990; Beg
and Baldwin, 1994) and its receptor as a gene target of NF-κB
(Santee and Owen-Schaub, 1996). Further, both TNFα and NF-
κB have been shown to regulate long-term potentiation (LTP)
(Albensi and Mattson, 2000), a form of synaptic plasticity and
a physiological phenomenon thought to underlie learning and
memory formation (Bliss and Lomo, 1973; Bliss andCollingridge,
1993).
The neutrophin nerve growth factor (NGF), which supports
cellular survival, is capable of activating NF-κB, as measured
by increased nuclear immunoreactivity for the p65 subunit,
in hippocampal cultured neurons (Bui et al., 2001), peripheral
glial cells (i.e., Schwann cells, Carter et al., 1996), and
pheochromocytoma (a.k.a. PC12) cells (Wood, 1995; Bui et al.,
2001), a cell line used as a neuronal model. In Schwann cells,
the effect is mediated through binding of NGF to p75NPR, a
neurotrophic receptor for which multiple neurotrophic factors
(i.e., brain-derived neurotrophic factor (BDNF); neurotrophin-
3) have a similar affinity. Neurotrophin-driven NF-κB activation,
however, may be specific to NGF, as neither BDNF nor
neurotrophin-3 activates NF-κB in Schwann cells (Carter et al.,
1996). Ceramide, a lipid found in cell membranes that also
possesses cell signaling properties, is capable of eliciting NF-κB
activation in many types of cells (Kolesnick and Golde, 1994),
including Schwann cells (Carter et al., 1996) and neurons, where
it induces cellular reactions similar to that seen with TNFα
(Goodman and Mattson, 1996). A 24-h exposure to ceramide or
TNFα increases Ca2+-current density in cultured hippocampal
neurons (Furukawa andMattson, 1998). Co-application of TNFα
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FIGURE 1 | Putative pathological production of Aβ and NF-κB signaling in neurons. Schematic representation of activators and neuronal gene targets of
NF-κB under conditions of excessive Aβ, as in Alzheimer’s disease. The transcription factor NF-κB is activated by several biological agents and thus may serve to
integrate various cell signaling pathways in neurons. In the canonical pathway, neuronal stimulation (e.g., by TNFα, calcium, glutamate) elevates intracellular Ca2+
levels, which activates IκB kinase and initiates phosphorylation and degradation of IκB. Evidence suggests that this Ca2+-mediated activation of NF-κB is
CaMKII-dependent. Once in a dimer state (prototypically p65/p50 subunits), NF-κB translocates to the nucleus and binds to the consensus sequence of neuronal
gene targets, many of which are involved not only in synaptic plasticity and memory but also amyloidogenic processing. For example, APP appears to serve as both
an activator and a gene target of NF-κB in neurons. The production of Aβ occurs via sequential cleavage of APP by BACE1, which yields sAPPβ, followed by cleavage
with γ-secretase, which yields an Aβ peptide. Aβ can aggregate into oligomers. Under conditions of supraphysiological/pathological Aβ levels, stimulation of NF-κB
appears ROS-dependent and may activate genes involved in the production of Aβ, including APP and/or BACE-1, further exacerbating amyloid dysregulation in AD.
Although gene transcription associated with the p65/p50 NF-κB complex (as shown here) can induce downstream gene expression, NF-κB-driven transcription can
also downregulate target genes through activation of p50 homodimers, which can repress gene expression. Aβ, amyloid beta; APP, amyloid precursor protein;
BACE1, beta-site APP cleaving enzyme 1; CaMKII, calcium-calmodulin kinase II; NF-κB, nuclear factor kappa b; ROS, reactive oxygen species; sAPPβ, secreted
amyloid precursor protein beta; TNFα, tumor necrosis factor alpha.
with κB decoy DNA prevented increases in Ca2+ current,
demonstrating the requirement of NF-κB in the observed effect
(Furukawa and Mattson, 1998).
NF-κB is, in turn, sensitive to Ca2+ signals and becomes
activated in response to elevations in intracellular Ca2+
(Meffert et al., 2003; Riquelme et al., 2011). For example,
high-frequency field stimulation of both hippocampal and
cortical neurons, which elevates levels of intracellular Ca2+ as
well as hydrogen peroxide, a reactive oxygen species (ROS),
induces nuclear translocation of p65 NF-κB (Riquelme et al.,
2011). Both endogenously present (e.g., after stimulation) and
exogenously-applied hydrogen peroxide activate NF-κB via p65
in hippocampal neurons (Riquelme et al., 2011). ROS are well-
documented initiators of NF-κB transcriptional regulation in
numerous cell types (for review, see Gloire et al., 2006) but not in
others (Schoonbroodt and Piette, 2000). The precise mechanisms
responsible for the cell specificity of ROS-induced NF-κB
activation are unknown. In neurons, however, stimulation-
induced NF-κB activation appears to be mediated by both Ca2+
and redox signaling.
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Various neurotransmitters, as may be expected based on
results of stimulation studies, can elicit NF-κB activity. Exposure
to N-methyl-D-aspartate (NMDA) induced a Ca2+-dependent
translocation of p65 NF-κB subunit to the nucleus and enhanced
nuclear binding of NF-κB in cultured cortical neurons (Ko et al.,
1998). This effect, however, was transient, lasting approximately
30min (Ko et al., 1998). Excessive stimulation via excitatory
neurotransmitters (e.g., glutamate, which binds to the NMDA
receptor) is lethal to neurons (Millar et al., 1987). NMDA
treatment leads to a rapid (i.e., milliseconds) increase in
intracellular Ca2+ (Ko et al., 1998). Neurons are exquisitely
sensitive to Ca2+ levels, and in the face of excessive intracellular
calcium, excitotoxicity can result (Randall and Thayer, 1992).
Ca2+ influx in and of itself is sufficient to induce NF-κB
binding activity in cortical neuronal cultures (Ko et al., 1998).
Moreover, blockade of NF-κB results in a decreased level of
NMDA-associated- neurotoxicity that is dose-dependent in these
neurons (Ko et al., 1998), similar to that found in neurons
from the hippocampus and cerebellum (Grilli et al., 1996b).
In hippocampal neuronal cultures, elevations in both glutamate
and Ca2+, implicated in excitotoxicity, activated NF-κB through
complexes containing p65/p50. Ca2+-induced NF-κB activation,
however, has been found to be calcium-calmodulin kinase II
(CaMKII)-dependent in cultured hippocampal neurons (Meffert
et al., 2003).
Although data reveal that induction of NF-κB occurs in
conjunction with cellular events known to be neurotoxic (e.g.,
excitotoxicity), resulting in neuronal death, and that NF-
κB inactivation appears neuroprotective, others have noted a
neuroprotective effect of NF-κB activation. In mice lacking the
p50 subunit, Yu et al. (1999) reported increased vulnerability
to excitotoxicity induced by kainic acid injection into the
hippocampus. Interestingly, this enhanced susceptibility was also
present in the side contralateral to the injection site, whereas the
non-injected side exhibited very little evidence of neuronal death
in control mice that received kainic acid injections. Thus, NF-κB
appears to confer a significant neuroprotective role in the brain.
Interestingly, the nature of the effect exerted by NF-κB as
either neuroprotective or neurotoxic may be activator-specific.
For example, activation of NF-κB (p65 and p50 subunits) by
insulin-like growth factor, which possesses a wide range of
biological actions in the CNS, including regulation of neural
development, neurogenesis, and synaptogenesis, has been shown
to induce neuroprotection in hypothalamic and cerebellar
granule neurons (Heck et al., 1999). In contrast, haloperidol,
a dopamine D2 receptor antagonist used to treat psychosis,
reduced cell survival despite inducing p65 nuclear translocation
and increasing NF-κB DNA binding activity in HT22 cells, a
clonal mouse hippocampal cell line (Post et al., 1998). These data
suggest neurotoxicity associated with NF-κB activation.
Several kinases implicated in learning and memory, including
protein kinase A (PKA) (Zhong et al., 1997, 1998), protein kinase
C (PKC) (Kim et al., 2010), and CaMKII activate NF-κB (Meffert
et al., 2003). PKA phosphorylates the p65 subunit of NF-κB (Lim
et al., 2011) and also directly associates with IκB, which, in turn
interacts with p65 (Zhong et al., 1997). In turn, PKA is a gene
target of NF-κB in neurons (Kaltschmidt et al., 2006). CaMKII
is abundant at synapses, whereas other CaMK members (e.g.,
CaMKIV) are concentrated in nuclei (Meffert et al., 2003).
More recently, studies have implicated NF-κB in maintaining
neuronal homeostasis, in which neurons adapt their activity in
efforts to preserve the stability of neural networks. Expression
of polo-like kinases (PLKs), which are involved in activity-
dependent synaptic remodeling via their ability to regulate
dendritic spine retraction, can activate NF-κB in hippocampal
neurons through the canonical pathway (e.g., involving IκB
degradation induced by IKK activation; Mihalas et al., 2013).
In p65-deficient cultured neurons, activation of PLKs resulted
in significantly greater dendritic spine and glutamate receptor
loss relative to activation of PLKs in control neurons, suggesting
that NF-κB serves as a counterbalance to prevent overshooting
of dendritic spine loss exerted by PLKs in response to high
excitatory activity (Mihalas et al., 2013).
NF-κB IN THE AD BRAIN
In addition to data demonstrating a role for NF-κB in
maintaining several physiological functions (e.g., synaptic
plasticity, learning, and memory), alterations to NF-κB are
also associated with pathological states, including AD. AD-
related neuropathology includes the characteristic Aβ plaque
formation and neurofibrillary tangles (NFT). Post-mortem
studies of the AD brain generally indicate increased expression
and/or activation of NF-κB, particularly in regions preferentially
affected in AD. For example, immunoreactivity for the p65
subunit was elevated in several neuronal elements (neurons
and their processes, neurofibrillary tangles, dystrophic neurites),
particularly in the hippocampus and entorhinal cortex in
AD patients relative to control subjects (Terai et al., 1996).
Immunoreactivity for p65 was particularly abundant in the
cytoplasm of stained neurons, with weaker nuclear staining.
Chen et al. (2012) found a robust (50%) increase in p65
protein levels in the frontal cortex of AD patients compared
to similar-aged controls. In basal forebrain, the proportion
of neurons immunoreactive for p65, either in the cytoplasm,
nucleus, or both, was increased in AD (Kitamura et al., 1997).
Kitamura et al. (1997) also reported increased p65 levels in
particulate, but not cytoplasmic fractions in the temporal cortex,
suggesting increased activation of p65-containing dimers in AD.
Ferrer et al. (1998) also noted increased p65 immunoreactivity
in nuclei of neurons specifically surrounding diffuse (early)
plaques in the hippocampus and cortex. In some neurons
with evidence of NFT, cytoplasmic immunoreactivity was
elevated, suggesting impairment of nuclear translocation in a
subset of affected neurons. Further, only neurons, not glia
cells, exhibited nuclear immunoreactivity for p65. In nuclear
extracts from the temporal lobe of AD patients, NF-κB
activation of p65/p50 was detected (Yan et al., 1995). Moreover,
immunohistochemical analysis indicated colocalization of p50
and pathological tau and upregulation of p50 in NFT-containing
neurons (Yan et al., 1995). Using an antibody raised against
epitopes exposed upon IκB degradation, indicative of NF-
κB in its active state, Kaltschmidt et al. (1997) documented
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immunoreactivity of pyramidal neurons and glia surrounding
early plaques and within plaques themselves in the limbic cortex
and hippocampus, whereas cells distal to plaques were devoid of
staining.
The above studies examining proteins of the NF-κB complex
are consistent with epigenetic studies examining NF-κB in
the AD brain. In addition to studies documenting increased
NF-κB at the protein level and evidence of its activation in
AD, Rao et al. (2012) reported hypomethylation of the NF-κB
promoter CpG region and a concomitant increase in mRNA
expression of p65 and p50 subunits in the frontal cortex
of those with AD relative to age-matched controls despite
hypermethylation of DNA at the global level. Of note is the
observation that NF-κB regulates expression of microRNAs,
small noncoding single strands of RNA that, in turn, regulate
the expression of multiple genes at the post-translational
level (Lukiw, 2012). NF-κB-mediated epigenetic factors have
also been implicated in disease, including AD (Zhao et al.,
2013), a topic that is the subject of recent reviews (Lukiw,
2012; Millan, 2014) and therefore is not addressed at length
here.
Although the majority of studies indicate elevations in
NF-κB complexes, Kaltschmidt et al. (1999) also reported
decreased nuclear localization of p65 in both neurons and
glia surrounding mature plaques in cortical tissue in AD
cortex relative to that from nondemented controls matched for
age, post-mortem delay, and fixation time, suggesting reduced
NF-κB activity associated with disease progression in AD.
Alternatively, these data suggest aberrations with activation and/
or nuclear translocation of NF-κB-activated dimers in AD. Such
an interpretation is consistent with the enhanced cytoplasmic
localization of p65-containing dimers found in AD-vulnerable
regions reported by Terai et al. (1996).
AMYLOIDOGENIC SIGNALING AND NF-κB
Several studies indicate a neurotoxic effect of Aβ, the biological
material considered central to AD, in primary embryonic
neuron cultures, neuron-like cell lines, and non-neuronal cells,
including cell death, increased susceptibility to excitotoxicity,
and mitochondrial dysfunction (Mattson, 1997). In human
fetal cultured neurons, Aβ treatment had no effect on survival
but increased susceptibility to glutamate in a dose-dependent
fashion and induced NFT-like pathological changes in the
presence of glutamate. No such effects, however, were found
in human astrocytes, suggesting a neuron-specific effect of
Aβ in human tissue (Mattson et al., 1992). In addition
to neurotoxic roles, studies also report a protective effect
of Aβ. For example, in young undifferentiated embryonic
cultured neurons, Aβ increased cell survival. In more mature
differentiated cultured neurons, however, Aβ application was
toxic, although this response was only seen with higher
doses, suggesting a developmental increased in the resilience
to the toxic effects of Aβ (Yankner et al., 1990). Others
report trophic effects at higher concentrations in embryonic
neurons (Whitson et al., 1989), including enhanced survival
(Whitson et al., 1989, 1990) and neuritic outgrowth (Whitson
et al., 1990). These data imply that the effects of Aβ are
both developmentally regulated, dose-dependent, and cell-
specific.
One mechanism by which Aβ may exert its effects (trophic or
toxic) appears to be via NF-κB signaling. Several studies confirm
regulation of NF-κB by Aβ (Behl et al., 1994; Kaltschmidt et al.,
1997, 1999; Bales et al., 1998; Valerio et al., 2006; Chami et al.,
2012) that appears to be mediated by ROS (Tanaka et al., 2002).
Aβ is capable of permeabilizing cell membranes (Glabe, 2006).
In rat cortical cultured neurons and in the neuron-like PC12
cell line, Aβ application induces ROS generation (Behl et al.,
1994), an activator of NF-κB (Meffert et al., 2003; Riquelme et al.,
2011). Thus, extracellular Aβ could permeabilize the neuronal
membrane and result in elevated ROS, which, in turn, would be
expected to activate NF-κB (see Figure 1).
The precise direction of the effect of Aβ on NF-κB (e.g.,
resulting in activation or inactivation), however, appears dose-
dependent and cell-specific. For example, Kaltschmidt et al.
(1997) found increased immunoreactivity for the activated
nuclear form of p65 in both neurons and glia from cerebellar
granule cell cultures with low-dose Aβ (0.1–1 µM), whereas this
effect was not seen with high-dose treatments. In a subsequent
study, Kaltschmidt et al. (1999) further found that activation
of NF-κB p65 induced by low-dose (0.1 µM) Aβ protected
granule cell cultures from the toxic effects of high (10 µM) Aβ
levels. Such data are consistent with the detection of Aβ under
physiological conditions and the severe neuronal loss seen in
vulnerable regions of the AD brain, where Aβ is elevated.
In contrast to the work of Kaltschmidt et al. Chami et al.
(2012) confirmed NF-κB activation with Aβ but only at high
(supraphysiological) levels in human embryonic kidney 293
(HEK293) cells. Bales et al. (1998) reported reduced levels of
constitutive p-65-mediated NF-κB activation with Aβ (25 or 50
µM) in rat cortical embryonic neurons, an effect dependent upon
upregulation of IκB levels tethering cytoplasmic NF-κB. These
data are in line with post-mortem studies indicating reduced
NF-κB p65 activation surrounding Aβ plaques (Kaltschmidt
et al., 1999). In glia cultures, however, NF-κB was activated in
response to Aβ treatment and resulted in increased expression
of inflammatory cytokines interleukin-1 beta and interleukin-
6, both downstream targets of NF-κB in glia (Aisen and Davis,
1994).
In addition to dose and cell-type differences, age appears to
be a factor in response to Aβ. In adult cortical neuron cultures,
Aβ42 (10 µM) treatment reduced the magnitude of p50 nuclear
translocation in neurons from middle-aged (11 month) rats,
with no effect of Aβ42 in neurons from old (24 month) rats
(Patel and Brewer, 2008). Co-application of Aβ42 with TNF,
however, significantly increased translocation of the p50 subunit
in both age groups (Patel and Brewer, 2008). This finding may
have particular relevance to the hippocampus in AD, a site of
neurogenesis in the human brain, and therefore, a site in which
neurons of varying ages reside (Eriksson et al., 1998).
In contrast to the aforementioned reports of hindered NF-
κB nuclear translocation in the presence of Aβ (Bales et al.,
1998; Patel and Brewer, 2008), Valerio et al. (2006) found
that Aβ induced nuclear translocation specifically of p65/p50
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dimers, whereas no such affect was found with c-Rel-containing
dimers in a neuroblastoma cell line. Thus, dimer specificity
may impart another element of regulation by which Aβ may
exert differential effects. Furthermore, Aβ induced cell death,
cytochrome c release, and downregulation of antiapoptotic Bcl-
XL, indicative of pro-apoptotic mechanisms, and also resulted
in increased intraneuronal levels of Aβ42. These effects were
prevented by blockade of NF-κB (Valerio et al., 2006). These data
are consistent with a pro-apoptotic role for p65/p50 dimers and
a neuroprotective role for dimers containing c-Rel (Pizzi et al.,
2002). Similar data were obtained in mouse cortical embryonic
cultures, whereby Aβ application (5 µM) was associated with
increased cell death and activation of p50/p65 NF-κB dimers,
whereas stimulation of c-Rel-containing NF-κB complex via
metabotropic glutamate receptors type 5 protected neurons from
Aβ toxicity (Pizzi et al., 2005).
Upon activation, NF-κB can, in turn, regulate Aβ levels, with
studies reporting p65/p50-mediated increases in Aβ in NT2N
human neurons derived from a teratocarcinoma cell line (Valerio
et al., 2006). The amyloid precursor protein (APP) is a neuronal
gene target of NF-κB (Grilli et al., 1995, 1996a). Thus, a logical
hypothesis would be that NF-κB activation results in increased
expression of APP, the proteolytic cleavage of which produces
Aβ. Under physiological conditions, NF-κB appears to negatively
regulate both APP and Aβ (Valerio et al., 2006; Chami et al.,
2012). In pathological conditions (e.g., overproduction of APP
and high Aβ levels), however, NF-κB activation upregulates
promotor activity of APP and the β-site APP cleaving enzyme
(BACE1), responsible for Aβ peptide production from APP
cleavage, resulting in elevated Aβ levels (Chami et al., 2012).
In turn, APP has been shown to positively regulate NF-κB, as
diminished APP results in a robust decrease in NF-κB activation,
and conversely, APP overexpression markedly increases NF-κB
activity (Chami et al., 2012).
Although the aforementioned studies suggest that NF-
κB-mediated elevations in APP production may result in
pathological elevations in Aβ, others report no effect of NF-κB
activation or inactivation on APP levels, but, rather point to
alterations in BACE1 expression, a recognized gene target of NF-
κB (Yang et al., 1998; Chen et al., 2012), as a key modulator of
NF-κB-associated increases in Aβ. The promoter for the BACE1
gene contains functional NF-κB binding elements (Chen et al.,
2012) that are highly conserved across species (Bourne et al.,
2007). In AD frontal cortex, p65 protein levels and BACE1
mRNA are upregulated compared to similar age controls (Chen
et al., 2012). In neuronal cell lines, p65 upregulated β-secretase
cleavage and production of Aβ; downregulation of p65 with non-
steroidal anti-inflammatory agents (NSAIDs) inhibited TNF-
mediated BACE1 elevations. No difference in APP protein levels
were detected in response to p65, thus elevated Aβ production
occurred via enhanced APP cleavage by upregulation of BACE1
(Chen et al., 2012). In other studies, however, activation of NF-
κB has been shown to suppress BACE1 expression in neuronal
cell lines, specifically through binding of p52/c-Rel dimers. After
Aβ treatment, however, NF-κB activation was associated with
increased BACE1 protein levels (Bourne et al., 2007). Whether
upregulation of this secretase resulted in further increases in
Aβ, however, was not examined. Although, the literature is
ambiguous regarding the precise mechanisms by which APP
and its cleavage into Aβ become neuropathological in AD, data
nonetheless indicate that conditions in which amyloidogenic
signaling is awry appear to self-propagate further amyloidogenic
dysregulation and that NF-κB appears to be centrally involved in
this process.
TAU PATHOLOGY AND NF-κB
In addition to amyloidogenic disturbances, alterations in tau,
resulting in NFT formation, constitute the other pathological
hallmark of the AD brain. In comparison to mechanisms
of Aβ production, the association between NF-κB and tau
pathology in AD has received much less attention. Tau is
a microtubule-associated protein preferentially expressed in
neurons that provides stability to microtubules, primarily
through phosphorylation; the hyperphosphorylation of tau is
linked to the formation of paired helical filamentous tau,
aggregation, and consequently intracellular NFT formation
(Šimic et al., 2016). The driving hypothesis in AD for decades
has been the “amyloid cascade hypothesis”, which argues that
amyloid perturbations precede tau pathologies in AD (Hardy
and Allsop, 1991; Hardy and Higgins, 1992). In the 3xTg model,
the only model to demonstrate both Aβ plaques and NFTs,
plaque deposition occurs prior to NFT development, consistent
with this hypothesis (Oddo et al., 2003a). Further, in a 3-D
culture system of AD using human neural progenitor cells with
mutations in genes involved in amyloidogenic signaling (e.g.,
APP, presenilin 1 (PS1)), tau pathology results (Choi et al.,
2014). Other lines of data, however, refute the amyloid cascade
hypothesis. For example, animal models of AD that overexpress
APP and exhibit intensive Aβ pathology lack NFT pathology
(e.g., CRND8; Chishti et al., 2001). Moreover, glycation of
paired-helical filamentous tau in neuroblastoma cells results in
elevations in APP and Aβ through NF-κB-dependent pathways
(Yan et al., 1995), suggesting a reciprocal relationship between
amyloidogenic and tau disturbances that may be mediated
through NF-κB. Additional research is needed to explore this
connection in AD.
CREB AND NF-κB
Among the most well-studied of the transcription factors
implicated in synaptic plasticity, learning and memory is
cAMP response element-binding protein (CREB). Decades
of research have established a robust role for CREB in
memory across species (see Kandel, 2012; Alberini and Kandel,
2014 for reviews). Although not considered a bona fide
gene target of NF-κB in neurons, several lines of evidence
confirm cross-talk between CREB and NF-κB, in line with a
vital role for both transcriptional regulators in learning and
memory. For example, in catecholaminergic locus coeruleus-
like cell line neurons, CREB silencing with siRNA inhibited
angiotensin-II mediated activation, nuclear translocation, and
DNA binding of p65-containing NF-κB dimers (Haack et al.,
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2013). Co-immunoprecipitation experiments confirmed no
direct association between CREB and NF-κB; however the co-
activator CREB-binding protein (CBP), a nuclear integrator
that can orchestrate multiple signaling cascades within a cell,
associated with CREB and with NF-κB (Haack et al., 2013).
Further, blockade of CBP prevented DNA binding of both CREB
and NF-κB p65 (Haack et al., 2013). These data suggest CBP
acts as a molecular bridge whereby these two transcriptional
regulators can act in concert in neurons in the absence of a direct
physical association.
In accordance with this, Haack et al. (2013) found that CREB
and the p65 subunit of NF-kB associate with different regions of
CBP, which would confer CBP with the ability to integrate CREB-
and NF-κB-mediated signals in tandem. Others, however, report
that PKA-induced phosphorylation of p65 at Ser276 and CREB at
Ser133 both involve association with the same KIX region of CBP
in nonneuronal cells, including Jurkat T and COS cells (Zhong
et al., 1998; Sheppard et al., 1999). In the nucleus, CBP is present
in limited supply (Kwok et al., 1994; Shenkar and Abraham,
1999). These data argue for a possible antagonistic relationship
between CREB and NF-κB, with competitive binding of each
to CBP and indicate another layer of transcriptional regulation
within the nucleus (Wadgaonkar et al., 1999). CBP-CREB and
CBP-NF-κB p65 binding was strengthened after lung injury
in vivo and was associated with similar upregulation of gene
targets of CREB andNF-κB, with evidence of competitive binding
of each to limited CBP (Shenkar et al., 2001). Negative regulation
of NF-κB p65-mediated transactivation and gene transcription
via PKA-mediated CREB signaling was reported in cultured
human monocytic and endothelial cells (Ollivier et al., 1996).
In the brain, reductions in neuronal NF-κB inhibit activation
of CREB through pathways involving PKA (Kaltschmidt et al.,
2006), known to activate CREB by Ser133 phosphorylation
(Walton and Dragunow, 2000). In healthy neurons (Yalcin et al.,
2003) and in pathological conditions (Lanzillotta et al., 2010),
p65 interacts with CBP. Moreover, Aβ treatment results in
downregulation of CBP that is rescued by TNFα pretreatment, an
effect that appears specific to neurons in the brain and is reliant
on TNFα-induced activation of NF-κB (Saha et al., 2009). Such
scenarios indicate a complex transcriptional network involving
CREB, NF-κB, and CBP and suggest CBP is another sensitive
regulator of synapse—nucleus signaling that may be involved in
activity-dependent transcription and plasticity.
CREB IN AD
As discussed above, evidence suggests that CREB and NF-
κB, upon activation by a variety of stimuli (injury/experience),
operate in a coordinated fashion to regulate transcription
of several target genes in neurons. Not surprisingly, then,
dysregulation of these transcription factors in neurodegenerative
disease, such as AD, could be expected to disturbmultiple cellular
processes that could cumulatively account for cognitive and
neurobehavioural disturbances in AD.
Several lines of research implicate altered CREB signaling
in AD. For example, in post-mortem AD brain tissue, CREB
activation is downregulated in the hippocampus, a region
susceptible to AD-related neuropathology. Under experimental
conditions, application of Aβ42 inhibits CREB activation (Tong
et al., 2001; Arunsundar et al., 2015) through decreased synaptic
NMDA-receptor density and corresponding reduced NMDA-
mediated current, as NMDA-receptor activation phosphorylates
CREB at Ser133 (Shaywitz and Greenberg, 1999). Under in vivo
conditions, elevated amyloid contributes to reduced CREB
activation, as TgCRND8 mice, characterized by early, excessive
brain amyloid, also exhibit diminished activation of CREB
(Yiu et al., 2011). To further understand the potential role of
CREB signaling in AD-mediated brain pathology and memory
impairments and its utility as a therapeutic target, Yiu et al.
(2011) conducted a well-designed series of experiments in
the TgCRND8 strain. Elevating CREB activation specifically
in the dorsal hippocampus using viral vectors rescued not
only spatial memory impairments but also several cellular
parameters, including dendritic stunting and reduced spine
density in TgCRND8 AD mice, suggesting the utility of CREB
to promote both morphological and neurobehavioral recovery
in AD. Interestingly, CREB is also present in mitochondria
(Cammarota et al., 1999) which exhibit morphological and
functional impairments in AD (Cabezas-Opazo et al., 2015)
and in mouse models of the disease (Chowdhury et al., 2015).
In mitochondria, CREB disruption impairs mitochondrial gene
expression, respiration (Lee et al., 2005), and biogenesis (Sheng
et al., 2012) as well as neuronal survival (Lee et al., 2005). Further,
phosphorylation of mitochondrial CREB increased after one trial
of inhibitory avoidance training, suggestive of an involvement
of mitochondrial CREB in activity-dependent neural changes
(Bevilaqua et al., 1999). Given these data, and the finding
that synaptic deficits are the strongest correlates of cognitive
dysfunction in AD (Terry et al., 1991), some have argued that
therapeutic approaches directed at CREB signaling pathways
constitute our best chance for treating AD (Teich et al., 2015),
given the diverse role of CREB in neuronal function and positive
neurobehavioral ramifications of its upregulation in AD models
(De Felice et al., 2007; Saura and Valero, 2011; Teich et al., 2015).
MANGANESE SUPEROXIDE DISMUTASE
(MNSOD)
An inducible antioxidant enzyme localized exclusively within
the mitochondria, MnSOD (a.k.a. SOD2) acts to scavenge free
radicals produced during cellular energy production, namely
oxidative phosphorylation (Sompol et al., 2008). MnSOD reduces
O2 conversion to H2O2 in the mitochondrial matrix. Compared
to other organs, the brain is considered particularly sensitive to
oxidative stress, as are neurons specifically. This is largely due to
high oxygen consumption levels coupled with a limited presence
of scavenger molecules relative to other systems. In lymphocytes
of AD patients, MnSOD mRNA levels are elevated, whereas the
total antioxidant status/trapping capacity is decreased in plasma
(De Leo et al., 1998). Thus, overexpression of MnSOD may
be a homeostatic response to mitochondrial perturbations and
changes in redox signaling in AD.
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In a study by Marcus et al. (2006), MnSOD protein levels,
as detected by immunohistochemistry, was found to be highly
elevated in multiple subfields (CA1, CA2/3, and CA4) of the
hippocampus in AD relative to age-matched non-AD controls;
however the lowest increase was seen in the CA1, where
AD-related upregulation of MnSOD was significantly lower.
Within-group immunoreactivity was similar in controls, whereas
immunoreactivity was lowest in the CA1 region relative to
other subfields in the AD group. Age was positively correlated
with MnSOD immunoreactivity in the control but not the
AD group, indicating that age-dependent upregulation of
antioxidant-scavenging capacity via MnSOD is diminished in
the AD hippocampus. Of note is the finding of extensive
pathology specifically in the CA1 subfield post-mortem in the
AD hippocampus (Marcus et al., 2006). In contrast, Kairane
et al. (2014) found diminished MnSOD activity in cortical
mitochondria from AD patients. Elevated mRNA may be a
homeostatic response to decreased activity of the enzyme such
that functional levels overall remain sufficient.
In further support of a relationship between redox
capacity and AD, mice heterozygote for MnSOD (resulting
in oxidative stress) crossed with transgenic mice Tg19959
mice overexpressing human amyloid precursor protein
(hAPP) displayed elevated Aβ levels as well as increased
Aβ plaque deposition relative to Tg19959 mice alone (Li et al.,
2004). Conversely, crossing this same strain with MnSOD-
overexpressing mice decreased plaque load, rescued spatial
memory deficits, and restored synaptophysin levels, indicating
synaptogenesis and reversal of AD-related synapse loss without
affecting Aβ levels (Dumont et al., 2009). Similar effects
were reported by Massaad et al. (2009) using the Tg2576
strain, also possessing hAPP carrying the Swedish mutation
(K670N:M671L). In this report, memory was improved, as was
the extent of plaque deposition, without affecting total Aβ levels.
The ratio of Aβ42 to Aβ40 was altered such that higher levels
of the less toxic Aβ40 were found in AD mice with enhanced
mitochondrial antioxidant capacity.
Despite these positive findings in mice in which MnSOD
is manipulated genetically and the reported alterations to
MnSOD in the AD brain, human genetic studies have failed to
find a significant association between polymorphisms affecting
MnSOD and AD risk (Ventriglia et al., 2005; Paz-Y-Miño et al.,
2015; de Mendonca et al., 2016). Thus, AD-related disturbances
in MnSOD likely occur secondary to other disturbances or as
a result of environmental factors. In accordance with this, in
APP/PS1 double transgenic mice overexpressing hAPP and PS1,
a genetic candidate for familial AD, social isolation compounded
AD-related memory impairments, increased MnSOD levels
(indicative of an adaptive response to oxidative stress), and
increased the ratio of Aβ42 to Aβ40 as compared to non-isolated
mice (Huang et al., 2011). Chronic exercise (treadmill running
for 20 weeks) upregulated MSOD activity, decreased Aβ42 levels,
and improved long-term memory in the passive avoidance test
in APP/PS1 Tg mice relative to sedentary mice, whereas no
such differences were found for wild-type (WT) mice (Bo et al.,
2014). Such data suggest that non-genetic manipulations that
alter MnSOD levels can affect both cognitive and amyloidogenic
aspects of AD. In support of MnSOD alterations as occurring
secondary to other disturbances, APP/PS1 had no decrease in
MnSOD protein levels at varying ages (2–14 mos) in either WT
(APP/PS1 heterozygotes) or Tg (APP/PS1 homozygotes) lines,
whereas MnSOD activity was decreased (Anantharaman et al.,
2006). Nitrotyrosine was increased in Tg mice as compared
to WT controls and contributed to the decreased enzymatic
activation. These authors suggest Aβ-induced elevations in
nitration negatively affect MnSOD activity (Anantharaman et al.,
2006).
Experiments in vitro in the APP/PS1 strain reveal elevated
levels of both MnSOD protein and activation in young cultured
neurons vs. neurons from WT mice and continued elevations in
both level and activity of MnSOD in neurons from both strains
with days in vitro (DIV), although this developmental increase
in neurons was to a lesser degree in APP/PS1 cultures. These
data indicate early oxidative stress in young neurons as well as
decreased mitochondrial antioxidant capacity in mature neurons
in this ADmodel (Sompol et al., 2008), consistent with reports in
humans (Marcus et al., 2006).
Several lines of research confirm involvement of MnSOD-
mediated redox regulation in AD and suggest that targeting this
enzyme may represent a useful therapeutic approach for the
disease. More work is needed, however, as little is known about
this key antioxidant enzyme or the effects of alterations to it
in the presence of another key pathological feature of AD in
addition to Aβ plaques, namely NFTs, as in the 3xTg mouse
(Oddo et al., 2003b). Perturbations toMnSODwould be expected
to arise as a consequence of alterations to signaling pathways
upstream, including NF-κB. The association between NF-κB and
MnSOD in AD-like conditions has only been investigated in
one study examining the modulatory effects of astrocytes on
Aβ-mediated neurotoxicity (Aguirre-Rueda et al., 2015). Here,
application of Aβ42 (5 µM over 24 h) was neurotoxic in neuron-
only cultures, resulting in a 50% decrease in cell viability relative
to neurons treated with Aβ40−1 (control treatment). This effect
was abolished in neurons co-cultured with astrocytes. Although
no decrease in cell viability was observed in astrocytes, Aβ42
application upregulated p65 in the nucleus in conjunction with
decreased IκB cytoplasmic protein levels, indicative of increased
activation of NF-κB complex with Aβ. In accordance, MnSOD
protein levels were increased (Aguirre-Rueda et al., 2015). The
presence of a similar relationship between Aβ, NF-κB and
MnSOD in neurons has not been directly confirmed in either
in vivo or in vitromodels of AD in which Aβ is in excess.
COPPER ZINC SUPEROXIDE DISMUTASE
(CUZNSOD)
Another key antioxidant molecule, CuZnSOD (a.k.a. SOD1), is
a superoxide scavenging enzyme located more diffusely in the
cytoplasm in contrast to the strictly mitochondrial localization of
MnSOD. This enzyme has been shown to be a downstream gene
target of p65-containing NF-κB complex in a neuronal cell line
(Rojo et al., 2004) and has also been implicated in AD. Recently,
the rs2070424 polymorphism of the SOD1 gene was found to
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be associated with protection from AD (Spisak et al., 2014).
Decreased CuZnSOD levels were found in peripheral blood
mononuclear cells in patients with mild cognitive impairment,
a prodrome to AD, and in the cortex of young 3xTg male mice,
suggesting early dysregulation in antioxidant capacity in the AD-
like brain (Mota et al., 2015). In double-transgenic AD mice,
chronic melatonin treatment reduced cognitive deficits, Aβ load,
and CuZnSOD mRNA expression, presumably in response to
decreased oxidative stress over time with melatonin treatment,
although the positive behavioral and amyloidogenic effects were
shown to occur independently of alterations to antioxidant
signaling (O’Neal-Moffitt et al., 2015).
CAMKII
Considered a fundamental synaptic protein, CaMKII is required
for the consolidation of memories from hippocampal-dependent
short-term to cortical-dependent long-term storage (Frankland
et al., 2001). CaMKII, regulated by the Ca2+/calmodulin
complex, can undergo autophosphorylation, which contributes
to the persistent activation of CaMKII at the synapse; it is
this self-perpetuating activity that positions CaMKII as a key
substrate in the physical translation of a transient experience
(e.g., learning) to a persistent biological change (e.g., in the
presence of experience-dependent neural plasticity; Sweatt,
2016). For example, mutations preventing autophosphorylation
inhibit LTP and memory formation (Giese et al., 1998). CAMKII
is also activated by and binds to L-type voltage-gated Ca2+
channels (Hudmon et al., 2005). Thus, Ca2+ homeostasis within
a neuron, the dysregulation of which has long been hypothesized
as a central, unifying feature of AD (Khachaturian, 1994), is
intricately linked to CaMKII signaling.
CaMKII exists as a holoenzyme consisting of a combination
of 12 subunits that are under the control of four genes;
CaMKIIα, β, γ, and δ. Of the subunits, CaMKIIα is the
most abundant in the brain, where it is highly localized to
glutamatergic synapses (Hanson and Schulman, 1992). The
various subunits display functional differences. For example,
CaMKIIγ is involved in activity-dependent transporting of
Ca2+/calmodulin from the membrane surface to the nucleus,
where it initiates CREB transcription (Ma et al., 2014). CaMKIIβ
regulates spine dynamics, as it binds to F-actin, regulates actin
turnover in dendritic spines, and contributes to maintenance of
mature spines (Fink et al., 2003; Okamoto et al., 2007). CaMKIIα
KO mice demonstrate impaired spatial learning (Silva et al.,
1992a) and hippocampal LTP (Silva et al., 1992b). Less is known
regarding CaMKIIδ in the CNS. Recently, Federman et al. (2013)
demonstrated that CaMKIIδ is upregulated in the hippocampus
specifically after long training times in a novel object recognition
task. Only extended training was associated with a persistent
memory and increased CaMKIIδ levels in mice. Moreover, they
confirmed, as have others (Kassed et al., 2004) that CaMKIIδ is
a neuronal gene target of NF-κB in the hippocampus, with data
implicating p65 and p50 subunits in this association. CaMKII
activates NF-κB (Lilienbaum and Israël, 2003), and Ca2+-
dependent activation of NF-κB is CaMKII-dependent (Meffert
et al., 2003). Interestingly, after activation, subunits within
the CaMKII holoenzyme can exchange with those from other
CaMKII holoenzymes, including inactivated ones, a process that,
in addition to autophosphorylation, also contributes to persistent
activation (Stratton et al., 2013). CaMKII, in turn, phosphorylates
CREB (Sun et al., 1994). Thus, in addition to its distinct
ability to self-regulate, CaMKII is both a neuronal effector and
downstream target of key transcription factors implicated in
learning, memory, and synaptic function.
In the AD brain, Western blotting studies have found no
differences in protein levels of CaMKIIα in homogenates from
either the hippocampus or cortex relative to non-demented
controls (Amada et al., 2005; Tannenberg et al., 2006). Analysis
using immunohistochemical methods however, suggests that
negative findings regarding CaMKIIα using Western blotting
techniques appear likely due to an upregulation of CaMKIIα
specifically in remaining CA1 neurons, which are reduced in
absolute numbers in AD (Wang et al., 2005). In pre-translational
studies in AD, CaMKII mRNA expression levels vary depending
on the specific gene (α, β, γ, and δ) and brain region examined
(Liang et al., 2008).
Autophosphorylation of CaMKII, particularly at threonine-
286 (T286), is critical for spatial memory formation and NMDA-
receptor-mediated LTP at CA1 synapses in the hippocampus
(Sweatt, 2016), both of which are aberrant in AD. In agreement,
T286 autophosphorylation is decreased in the AD hippocampus
(Amada et al., 2005). Others have reported subcellular-
specific differences in T286 autophosphorylation, including
a downregulation at synapses and within dendrites but an
upregulation in somata in both the CA3 and dentate gyrus
hippocampal subfields (Reese et al., 2011).
In animal models of the disease, similar dysregulation of
CaMKII signaling is found. In the hippocampus of APP/PS1
mice, Cav1.2 and phospshorylated CaMKII were decreased, as
were the number of cells immunoreactive for phosphorylated
CaMKII and Cav1.2 (Min et al., 2013). Calmodulin levels, as
measured by Western blotting, were elevated. Phosphorylation
of CREB was also decreased, consistent with reduced CaMKII-
mediated activation, as was a downstream target of CREB, BDNF.
In hippocampal neuron cultures, Aβ42 treatment upregulated
Cav1.2 and elevated intracellular Ca2+ levels. However,
phosphorylation of CaMKII was decreased. Calmodulin levels
were unchanged (Min et al., 2013). Thus, in both AD models,
although signaling cascades upstream of CaMKII activation
were in opposing directions, in both cases, activation of CaMKII
was reduced. In vivo, this was associated with a corresponding
reduction of its downstream targets implicated in synaptic
plasticity, learning and memory in the AD-like brain.
In this same strain, Gu et al. (2009) found no change in
overall levels of CaMKIIα, β, or phosphorylated CaMKII in
the cortex. Subcellular localization, however, was affected, as
all forms of CaMKII examined (α, β, or phosphorylated) were
elevated in the cytosol and reduced in synaptosomes relative
to WTs. CaMKII was also reduced in cultured cortical neurons
after Aβ application, similar to findings reported in hippocampal
cultures (Min et al., 2013), with a reduction in the density of
CaMKII at synapses. Further, the membrane localization of the
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GluR1 subunit, important for alpha-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor stabilization, was
reduced, as was an AMPA-mediated ionic current. Importantly, a
similar effect on AMPA-mediated current resulted after CaMKII
knockdown and was prevented by CaMKII overexpression (Gu
et al., 2009).
These data highlight the importance of CaMKII dysregulation
in receptor destabilization and impaired excitatory synaptic
transmission associated with AD. Literature supports the notion
that enhancing CaMKII activity can alleviate neuropathological
and neurobehavioural features of AD (e.g., Zeng et al., 2010;
Logan et al., 2011; Wang et al., 2013). Naturally derived Aβ
oligomers, either from cultured transgenic cells that secrete hAPP
(Shankar et al., 2007) or from the brains of those with AD
(Shankar et al., 2008), reduced spine density and synapses in
pyramidal neurons from mouse hippocampal slice cultures in
a reversible fashion (Shankar et al., 2007, 2008). No such effect
was noted with application of Aβ monomers or intact amyloid
dense core plaques; toxic effects were only noted when these
plaques were solubilized with formic acid (Shankar et al., 2008).
Importantly, studies have demonstrated that the detrimental
effects of Aβ on spine formation, an integral component of
the synapse, are reversible (Shrestha et al., 2006; Shankar et al.,
2007). Activation of CaMKII in neurons is sufficient to elicit
spine formation, which occurs in an activity-dependent manner
(Jourdain et al., 2003), which could be one mechanism (Fitzjohn
et al., 2006) to partially account for noted improvements with
treatments upregulating CaMKII.
POSTSYNAPTIC DENSITY PROTEIN-95
(PSD-95)
PSD-95 is an integral protein involved in regulating activity-
dependent synaptic plasticity. Residing in the postsynaptic
density, PSD-95 is involved in numerous processes
including trafficking and anchoring of receptors and ion
channels, regulation of spine density, and modulation of
neurotransmitter—receptor communication and synaptic
strength (Fitzjohn et al., 2006). It can bind to several other
synaptic proteins, including NMDA receptors (Niethammer
et al., 1996) and neuroligins (Irie et al., 1997; Song et al.,
1999). Through its interaction with neuroligins, PSD-95 also
contributes to determining the ratio of inhibitory to excitatory
synaptic contacts (Shankar et al., 2007). Consistent with a
prominent role for PSD-95 in regulating the synapse, mice
deficient in PSD-95 exhibit deficits in spatial learning and
alterations in LTP (Migaud et al., 1998), long-term depression
(Park et al., 2008), and spine density (Vickers et al., 2006).
In a series of experiments, Boersma et al. (2011) identified
PSD-95 as a gene target of NF-κB inmouse hippocampal cultured
neurons. Here, p65 was present and enriched particularly in
dendritic spines of hippocampal pyramidal neurons. Moreover,
a loss of p65 significantly reduced protein levels of PSD-95,
whereas excitatory synaptic input activated NF-κB, increased
spine density, and upregulated PSD-95 mRNA. These data
strongly suggest a role for NF-κB in synapse regulation and
activity-dependent synaptogenesis that occurs through PSD-95
regulation.
Evidence suggests that PSD-95 may be particularly sensitive to
Aβ. In cultured cortical neurons, application of Aβ40 selectively
downregulated PSD-95, whereas levels of several other synaptic
proteins, including CAMKII, growth-associated protein (GAP-
43), and AMPA receptor subunit GluR2 were unchanged with
treatment. In addition, the level of the presynaptically-localized
synapsin was also unaffected. Although AMPA receptor levels
were not different after Aβ treatment, the Aβ-induced loss of
PSD-95 was associated with reduced AMPA receptor density at
the cell surface (Roselli et al., 2005), in accordance with a role for
PSD-95 in receptor trafficking. Onemechanism by which Aβmay
downregulate PSD-95 may be through NF-κB signaling, given
that several studies demonstrate NF-κB activation in neurons
by Aβ (Kaltschmidt et al., 1997, 1999; Pizzi et al., 2005; Valerio
et al., 2006; Chami et al., 2012), with specific NF-κB homodimers
capable of suppressing gene transcription upon translocation to
the nucleus (Zhong et al., 2002). However, this has not been tested
in relation to Aβ-induced repression of PSD-95.
Despite the specificity of Aβ on PSD-95 reported in vitro,
post-mortem studies provide contradictory findings related to
the status of PSD-95 in AD, as reviewed in detail by Savioz
et al. (2014), including negative findings as well as increased and
decreased levels being reported in the literature. The authors
speculate that regional differences in susceptibility and/or
differences in disease severity may account for the reported
inconsistencies. In contrast, generalized reductions in PSD-95 are
reported in studies using various models of AD-like pathology,
including amyloidogenic Tg2576 mice and mice expressing
human tau. In PS1 mice, however, PSD-95 is upregulated in the
frontal cortex (Savioz et al., 2014). In the 5xTg model, in which
amyloid pathology is robust and early, Shao et al. (2011) found
an age-dependent shift in PSD-95 localization from dendritic
to somatic compartments in the hippocampus, confirming an
aberrant subcellular distribution of this postsynaptically rich
protein in association with AD-like neuropathology.
EARLY GROWTH RESPONSE (EGR)
FACTORS
The early growth response family of transcription factors consists
of four members (Egr1-4) that have been identified in the CNS
and appear to be involved in regulating gene transcription
in association with activity-dependent plasticity, learning and
memory. Their specific functions in the CNS, however, are not
fully elucidated (Poirier et al., 2008). Of these, Egr1 (a.k.a. NGFI-
A, Krox24, Zif268) is the most well-studied in terms of its
role in brain function. As an inducible immediate-early gene,
the product of Egr1 has been implicated as a key molecular
mechanism by which activity-dependent signaling from the
postsynaptic receptor can be transmitted to the nucleus to initiate
gene transcription required for the induction of learning and
memory-associated neural changes. Consistent with its function
as an immediate-early gene, biophysical characteristics of Egr1
include fast (millisecond) activation in response to stimuli and
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transient expression (Veyrac et al., 2014). Egr1 is implicated in
synaptic transmission (Jones et al., 2001; Penke et al., 2013),
learning (Guzowski et al., 2001), memory consolidation (Jones
et al., 2001; Penke et al., 2013; although see Lee et al., 2004)
and reconsolidation (Lee et al., 2004), and more recently in
the recruitment of new neurons into functional networks after
hippocampal neurogenesis (Veyrac et al., 2013). Coincident
with these roles, levels of Egr1 protein are higher in brain
regions involved in these functions, including the hippocampus,
particularly the CA1 region, and cortex relative to other regions
(Beckmann and Wilce, 1997).
Studies identify Egr1 as a probable gene target of NF-
κB in neurons. For example, in mice, hippocampal-mediated
recognition memory requires Egr1 expression and is dependent
upon NF-κB activation (Zalcman et al., 2015). Further, gene
array analysis of hippocampal tissue identified Egr1 as a memory-
associated gene candidate of NF-κB and further reported NF-κB
binding sequences in the Egr1 promoter region (Ahn et al., 2008).
In other tissue, Egr1 has been identified as a bona fideNF-κB gene
target (Carayol et al., 2006), but additional studies are needed to
establish this unequivocally in neurons.
Another member of the Egr family, Egr2 (a.k.a. Krox20) has
recently been confirmed as a gene target in neurons (Nafez
et al., 2015). In mouse hippocampal slices, LTP upregulates
Egr2 (Williams et al., 1995) in an NF-κB-dependent manner
that requires p50 (Nafez et al., 2015). Studies of the behavioral
impact of Egr2 regulation, however, have found a gain of function
in Egr-2-conditional KO mice lacking forebrain expression, as
reflected by improved motor skill learning and enhanced long-
term memory (24 h) in an object recognition task (Poirier et al.,
2007). These data are surprising, given observed elevations
in Egr2 after experimental paradigms mimicking learning and
memory in vitro and are in contrast to behavioral studies in
mice with mutations affecting Egr1 and Egr3, which result
in both memory and LTP impairments (Poirier et al., 2008).
In Egr1 mutants, however, only late-phase LTP and long-
term memory are impaired (Jones et al., 2001), whereas Egr3
mutations result in more widespread impairments, affecting
both early- and late-phase LTP and short- and long-term
memory formation (Li et al., 2007). Interestingly, using different
models to examine experience-dependent gene expression, Egr2
upregulation in multiple brain regions appeared independent of
CREB (Lemberger et al., 2008). Collectively, these data illustrate
potent yet disparate involvement of the Egr transcription factor
family in several forms of activity-dependent plasticity and
memory.
In AD, dysregulation of Egr1 is fairly well-established. In
a recent microarray study focusing on the CA1 hippocampal
subfield, Egr1 was deemed a central regulator of genes implicated
in AD (Acquaah-Mensah and Taylor, 2016). Post-mortem studies
consistently confirm upregulation of Egr1 in both the cortex
(Shim et al., 2003; Lu et al., 2011; Hendrickx et al., 2013)
and hippocampus (MacGibbon et al., 1997; Gómez Ravetti
et al., 2010; Lu et al., 2011). Further, Egr1 and tau were
colocalized in the AD hippocampus (MacGibbon et al., 1997).
Interestingly, Egr1mediates tau phosphorylation (Lu et al., 2011),
an excess of which contributes to the formation of pathological
species of tau and subsequent NFT. Thus, data suggest that:
(1) Egr1 upregulation may be a contributing factor to NTF
development in AD, and (2) strategies that reduce AD-mediated
Egr1 overexpression may offer therapeutic benefit for the disease.
Studies using either animal or in vitro models also confirm
dysregulation of Egr1 in AD, although the direction of the effect
differs in these models from the human condition. For example,
intracerebroventricular injection of soluble Aβ42 oligomers
decreased phosphorylation of CREB and reduced mRNA levels
of its target gene, BDNF (discussed below), consistent with data
in human AD. However, Egr1 was also decreased, in contrast to
the literature on AD (Arunsundar et al., 2015).
In mice, hippocampal Egr1 is elevated after hippocampal-
dependent learning tasks, including the Morris water maze and
inhibitory avoidance training (Bekinschtein et al., 2007; Porte
et al., 2008). In Tg2576 and APP751SL mice, characterized by
overexpression of hAPP, hippocampal Egr1 was significantly
decreased relative to WT controls after MWM training, in which
mice were impaired on learning and memory phases. These
data are in agreement with studies documenting epigenetic
downregulation of Egr1 in neurons by APP (Hendrickx et al.,
2013), a process that has shown to be mediated by CREB
(Hendrickx et al., 2014), as overexpression of hAPP would be
expected to further suppress Egr1 to a pathological degree.
Studies thus far, however, have not investigated the relationship
between amyloidogenic processes, Egr1 and tau pathology or
how NF-κB alterations potentially link these changes in an AD
model in which NFTs occur (e.g., 3xTg strain). Further studies
are required to understand the disparate data between AD and
experimental models regarding Egr1 transcriptional regulation
and cognitive impairments associated with AD. Data thus far,
however, indicate that in the AD and AD-like hippocampus,
Egr-1-associated activity-dependent transcriptional regulation
is altered, which would be expected to exert potent and
detrimental effects on synaptic function and ultimately
cognition.
Regarding Egr2, few studies have examined this transcription
factor in AD. In the aforementioned study by MacGibbon
(MacGibbon et al., 1997), although immunohistochemical
processing did not reveal any obvious changes in Egr2, semi-
quantitative analyses were not conducted. We are not aware of
any other study investigating potential Egr2 dysregulation in AD,
nor have any studies investigated Egr2 in models of the disease.
In light of studies demonstrating enhanced cognition in cases of
Egr2 deficiency, it would be interesting to evaluate basal levels
of this Egr family member in animals exhibiting AD-associated
cognitive dysfunction. Our laboratory has confirmed NF-κB-
dependent upregulation of Egr2 after LTP in the hippocampus
(Nafez et al., 2015). Whether this upregulation persists in the
AD-like brain, however, is unknown.
CYCLO-OXYGENASE-2 (COX-2)
An important regulator of the inflammatory response after
injury in neurons is COX-2 (a.k.a. prostaglandin H2 synthase),
a rate-limiting enzyme that produces prostaglandin synthase via
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conversion from arachidonic acid. After cerebral ischemia, COX-
2 is severely upregulated, specifically near the infarct border,
where it contributes to delayed neuronal death (Nogawa et al.,
1997). Interestingly, COX-2 is also induced in the hippocampus
after high-frequency stimulation (Yamagata et al., 1993), and its
blockade impairs LTP (Chen, C. et al., 2002; Cowley et al., 2008)
as well as spatial memory acquisition (Rall et al., 2003; Cowley
et al., 2008) and retention (Teather et al., 2002), confirming
its importance in regulating synaptic plasticity, learning, and
memory.
The NF-κB-COX-2 signaling pathway has been investigated in
AD. Epidemiological data suggests that NSAIDs as a class confer
neuroprotection against AD onset and clinical progression, with
purported effects through regulation of COX isoforms (Pasinetti,
1998). In AD, COX-2 expression is elevated in frontal cortex and
in neuron-like cell lines treated with Aβ (Pasinetti and Aisen,
1998). NF-κB activation positively regulates COX-2 expression
in neurons (Kaltschmidt et al., 2002), and inhibitors of NF-κB,
such as aspirin, result in a corresponding decrease in neuronal
COX-2 levels (Kaltschmidt et al., 2002). Further, in aging and
in AD, NF-κB binding activity of p65/p50 dimers and COX-
2 mRNA were highly correlated (r2 = 0.87; r = 0.93) in
cortical tissue (Lukiw and Bazan, 1998). Such data argue for
therapeutic benefit with measures that reduce NF-κB and COX-
2 downstream, for which there has been support in AD models.
In Tg2576 AD mice, pharmalogical inhibition of COX-2 with
(NSAIDS) alleviated Aβ-induced memory and synaptic plasticity
deficits that are characteristic of this model, effects that occurred
independent of decreased levels of Aβ oligomers or inflammation
(Kotilinek et al., 2008). In APP/PS1 mice crossed with mice
overexpressing COX-2, females exhibited deficits in spatial
working memory that were resolved with COX-2 inhibition
by pharmacological blockade. No such effects were seen in
male transgenic mice. In both sexes, COX-2 overexpression
did not affect Aβ plaque load (Melnikova et al., 2006), similar
to previous reports (Kotilinek et al., 2008). Others (Guzmán
et al., 2009) also reported female-specific deleterious effects of
pharmacological blockade of COX-2 in normal mice, including
impaired spatial memory retention, with no effect in males
(Guzmán et al., 2009). The authors speculated that factors such as
differences in drug metabolism and intersecting effects between
sex hormones (e.g., estradiol) and COX-2 may explain sex-
dependent effects of COX-2 inhibition on learning and memory
performance.
BDNF
The neurotrophin BDNF is ubiquitously expressed in the
CNS, suggesting it plays a fundamental role in brain function.
Accordingly, BDNF has been shown to participate in multiple
neural processes, such as energy metabolism, neurogenesis,
neuronal differentiation, and activity-dependent synaptic
plasticity, learning, and memory (Noble et al., 2011; Lu et al.,
2014). BDNF is regulated by neural activity (Lu et al., 2013)
and is also a target of key transcriptional regulators in neurons,
including CREB (Tao et al., 1998) and NF-κB (Marini et al.,
2004), whose activation elevates BDNF expression (Lipsky et al.,
2001). Egr1 has also been shown to bind to BDNF, resulting in
decreased expression in neural tissue (Hendrickx et al., 2013).
Additionally, BDNF is regulated by APP (Hendrickx et al.,
2013), which has also been shown to suppress BDNF levels.
Although, studies demonstrate BDNF elevations in response to
CREB activation (Tao et al., 1998), others (Hendrickx et al.,
2013) have confirmed CREB-induced decreases in BDNF via
regulation through APP. Further, BDNF positively regulates
processing of APP by favoring non-amyloidogenic pathways
(Rohe et al., 2009), suggesting complex regulatory networks
modulating BDNF status in the CNS that involve a key protein
implicated in AD. Although APP is able to downregulate BDNF
(Hendrickx et al., 2013), APP positively regulates NF-κB, an
inducer of BDNF expression (Lipsky et al., 2001). Thus, studies
indicate multiple pathways that appear to tightly regulate BDNF
expression, which is consistent with its divergent roles in brain
function.
Both post-mortem and antemortem studies of AD indicate
alterations in BDNF expression. Blood serum studies report
increased BDNF in early-stage disease (Laske et al., 2006),
which may be an initial compensatory response, whereas post-
mortem studies indicate severe decreases in brain BDNF levels
(as reviewed in Zhang et al., 2012). Early-stage increases may be
indicative of an initial compensatory response in the disease, a
hypothesis supported by animal and in vitro AD models (Diniz
and Teixeira, 2011). Given its pleiotropic roles in the CNS, such
deficits in levels of this trophic factor would be expected to
contribute diffusely to neural dysfunction in AD.
NEUROPEPTIDE Y
First identified as a gene target of NF-κB inmouse neuroblastoma
cells (Musso et al., 1997), neuropeptide Y is an orexigenic
peptide that plays a key role in regulating feeding behavior, with
a more recently identified functional contribution to learning
and memory (Borbély et al., 2013). Neuropeptide Y and its
receptors, localized extensively throughout the brain, have been
implicated in AD, where levels of both are significantly reduced
in the hippocampus and cortex (Beal and Martin, 1986). The
ramifications of this in the context of AD are unclear, as are
the potential contributions of AD-related NF-κB dysfunction
to the observed depression of neuropeptide Y. Animal studies,
however, document neuroprotective effects of neuropeptide Y
against several insults, including Aβ toxicity (Croce et al., 2012,
2013; Angelucci et al., 2014), in some cases, through modulation
of a downstream target of NF-κB, BDNF (Croce et al., 2013).
CONCLUSIONS
As can be appreciated from a survey of the literature, our current
understanding of the mechanisms by which Aβ influences
NF-κB-driven transcription and vice versa is riddled with
discrepancies and inconsistencies. These are likely influenced by
methodological differences related to the specific tissue, cell, age,
and NF-κB-dimer composition under investigation. Moreover,
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the majority of studies thus far have investigated the subunits
that comprise the prototypical p65/p50 dimer, with few studies
investigating other NF-κB subunits (e.g., c-Rel, RelB, or p52) in
the context of AD. This is an important consideration, given
evidence discussed above indicating differential actions of NF-
κB based on the subunit composition. Additionally, although
several studies confirm a reciprocal relationship between Aβ
and NF-κB, there is a paucity of research examining brain
NF-κB, its relationship to AD pathology, and its putative
therapeutic potential under conditions in which both cardinal
neuropathological features of AD are present, specifically in
the presence of excess Aβ AND NFTs. Lastly, the majority of
studies examining NF-κB in AD have used model systems from
embryonic origins or cancerous cell lines. Given that aging is
a significant risk factor for AD (Corrada et al., 2010), research
investigating NF-κB in AD using aged animal models or cells
derived from aged animals as model systemsmay generate results
that are more generalizable to clinical research in the hopes of
translating basic findings into efficacious therapies for the disease
(Wallace and Howlett, 2016).
The gene targets of NF-κB in neurons are members of diverse
functional classes (see http://www.bu.edu/nf-kb/gene-resources/
target-genes/ for a comprehensive list of currently known
targets organism-wide, care of Dr. Gilmore, Boston University),
including other transcription factors, antiapoptotic proteins,
neurotrophic factors, synaptic proteins, antioxidant enzymes,
and neuropeptides. Thus, alterations to the NF-κB complex,
as has been well-documented in the context of AD, would be
expected to have pervasive effects on brain function. Therefore,
strategies that impact NF-κB would be, in a similar vein, expected
to have potentially broad therapeutic value in treating neuronal
dysfunction in AD. On the other hand, its far-reaching effects
within an organism, including potent roles in not just cognition
but immunity, necessitate a detailed understanding of NF-κB
signaling in the CNS so that the ramifications of altering NF-κB
for therapeutic gain are more fully appreciated.
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